Autologous MSCs
Cells originate from the same patient who will receive the final preparation. Collection, manufacturing time, donor health and cell quality remain important variables.
CELLMEX Scientific Library
MSC Therapy
Mesenchymal stromal cell therapy is a developing field of cellular medicine in which characterised MSC preparations are investigated for their immunomodulatory, paracrine, trophic and tissue-supporting biological activities.
Scientific Definition
A cellular intervention defined by its source, process and intended use
MSC therapy refers to the clinical or investigational use of preparations containing mesenchymal stromal cells obtained from a defined tissue source and processed under controlled laboratory conditions.
MSCs are commonly studied from bone marrow, adipose tissue and perinatal tissues such as umbilical-cord tissue. Cells from different sources may differ in growth, immunological, secretory and functional characteristics.
The abbreviation MSC should not be interpreted as one standardised treatment. Every preparation must be evaluated according to its source, donor, manufacturing process, passage, formulation, quality attributes, dose and intended clinical application.
Allogeneic MSCs
Cells originate from a separate qualified donor and may support controlled banking, manufacturing and preparation for more than one recipient.
Culture-Expanded MSCs
Cells are isolated and expanded through one or more laboratory passages to generate a defined population and final dose.
Product Identity
The name MSC does not define the complete product
Biological activity and clinical performance may be influenced by multiple donor, tissue, laboratory and formulation variables.
Tissue Source
Bone-marrow, adipose and perinatal-tissue MSC populations may exhibit different expansion, secretory and functional characteristics.
Donor Characteristics
Donor age, health, medications, biological history and tissue condition may influence the starting material.
Culture Conditions
Media, supplements, oxygen tension, cell density, culture surface and environmental conditions can affect the resulting population.
Passage and Expansion
Extended culture may alter proliferation, morphology, senescence, gene expression and functional activity.
Cryopreservation
Freezing, storage, thawing and post-thaw recovery may affect viability, membrane integrity and functional characteristics.
Final Formulation
Cell concentration, carrier solution, container, transport, holding time and administration conditions form part of the final product.
Biological Activity
MSC activity extends beyond direct differentiation
Many proposed MSC effects are associated with transient signalling, immune interaction and support of the local tissue environment rather than routine permanent engraftment.
Paracrine Signalling
MSCs release soluble and vesicular factors capable of influencing nearby cells and tissues.
- Cytokines and chemokines
- Growth and trophic factors
- Extracellular vesicles
- Matrix-modulating factors
Immunomodulation
MSCs may interact with innate and adaptive immune-cell populations under defined biological conditions.
- T-cell responses
- B-cell activity
- Macrophage behaviour
- Dendritic and natural-killer cells
Trophic Support
MSC-derived signals are studied for their effects on cell survival, endogenous repair responses, vascular signalling and tissue homeostasis.
Extracellular-Vesicle Release
MSCs release membrane-enclosed vesicles carrying proteins, lipids and nucleic acids involved in intercellular communication.
Matrix and Tissue Environment
MSC-associated factors may influence extracellular matrix production, degradation, fibrosis-related signalling and cell–matrix interaction.
Differentiation Capacity
MSC cultures can demonstrate osteogenic, adipogenic and chondrogenic differentiation in vitro. This does not establish that administered cells routinely replace complex tissues in patients.
Laboratory Manufacturing
From qualified tissue to a final cellular preparation
Each manufacturing stage can influence identity, viability, purity, consistency and biological function.
Donor and Source Qualification
Document donor eligibility, tissue source, collection procedure, transport conditions and traceability.
Cell Isolation
Recover a stromal-cell population using a process appropriate to the selected tissue.
Primary Culture
Establish adherent cells under defined media, supplement, environmental and monitoring conditions.
Controlled Expansion
Expand cells within established limits for passage, confluence, growth rate and culture duration.
Harvest and Processing
Recover, wash, count and prepare the cells while controlling contamination, aggregation and loss of viability.
Cryopreservation or Direct Preparation
Cells may be cryopreserved under qualified conditions or processed directly according to the manufacturing model.
Final Formulation
Prepare the required concentration, carrier, container and final presentation under defined handling conditions.
Release Review
Review product identity, viability, microbiological safety, documentation and product-specific acceptance criteria.
Quality Control
Clinical suitability cannot be determined by cell count alone
A complete assessment should address identity, purity, safety, stability, consistency and function.
Identity
Morphology, plastic adherence, immunophenotype and other product-specific cellular characteristics.
Viability and Cell Number
Viable-cell concentration, total dose, recovery and post-thaw or post-processing quality.
Microbiological Safety
Sterility-related testing, mycoplasma assessment and endotoxin control where applicable.
Purity
Evaluation of unwanted cells, residual process materials, aggregates and other potential impurities.
Functional Assessment
Fit-for-purpose assays linked to the proposed biological activity or intended mechanism.
Consistency and Stability
Review of passage, batch variability, storage, transport, thawing and defined product lifetime.
Clinical Pathway
Clinical consideration begins with the patient—not the product
A responsible pathway examines diagnosis, evidence, alternatives, patient-specific risk and the exact cellular preparation being considered.
Medical Evaluation
Review diagnosis, disease stage, medical history, current treatment, medications and relevant risk factors.
Records Review
Examine clinical reports, imaging, laboratory results and prior responses to conventional care.
Evidence Assessment
Compare the proposed intervention with available human evidence, alternatives and the patient's clinical objectives.
Informed Decision
Discuss uncertainty, potential risks, expected limitations, costs and follow-up requirements.
Monitoring and Follow-Up
Document safety, tolerability, clinical status, function and relevant outcome measures over time.
Administration Strategy
Route of administration changes exposure and risk
Administration must be determined by the specific product, target tissue, intended mechanism, clinical evidence and patient condition.
Local Administration
Delivery near a selected anatomical site may increase local exposure but requires appropriate procedural technique, imaging where indicated and tissue-specific risk assessment.
Systemic Administration
Intravascular administration produces a different biodistribution and may introduce product-specific vascular, coagulation, immune and infusion-related considerations.
Specialist Routes
Intra-arterial, intrathecal or other specialised routes require a strong scientific rationale, appropriate clinical facilities and qualified specialists.
Translational Research
Principal areas of MSC therapy investigation
Evidence varies substantially by indication, cell source, manufacturing process, dose, route and study design.
Musculoskeletal Medicine
Research includes cartilage, bone, tendon, ligament and inflammatory joint environments.
Immune-Mediated Disorders
Clinical research examines MSC interaction with inflammatory and immune pathways in defined disease settings.
Neurological Disorders
Studies investigate neuroinflammatory, trophic and vascular mechanisms rather than assuming direct neuronal replacement.
Wound and Vascular Biology
Research examines angiogenic signalling, wound repair, cellular survival and matrix remodelling.
Organ Injury
Pulmonary, cardiac, renal and hepatic studies investigate immunological and tissue-support mechanisms.
Manufacturing Science
Development focuses on consistent expansion, cryopreservation, potency testing, formulation and clinically relevant release criteria.
Clinical and scientific qualification
MSC preparations obtained from different tissues, donors or manufacturing processes cannot be assumed to be biologically or clinically equivalent.
Laboratory evidence, animal studies and biological plausibility do not independently establish safety or clinical effectiveness in human patients.
Many proposed MSC applications remain investigational or jurisdiction-dependent. Availability at a clinic does not by itself establish regulatory authorisation, clinical efficacy or professional consensus.
MSC therapy should not be described as an established cure or guaranteed method of regenerating cartilage, neurons, organs or other tissues without product-specific human evidence.
Patients should not discontinue conventional medical care or delay an established treatment solely to pursue an experimental cellular intervention.
The CELLMEX Approach
Science, manufacturing and clinical medicine must remain connected
Define the Cellular Product
Identify the tissue source, donor model, manufacturing history, passage, formulation and final cellular characteristics.
Establish Quality Criteria
Review identity, viable-cell dose, purity, microbiological safety, stability and relevant functional characteristics.
Evaluate the Patient
Consider diagnosis, medical history, disease stage, conventional alternatives, contraindications and realistic objectives.
Document Clinical Translation
Use informed consent, defined administration, safety monitoring, follow-up and appropriate outcome documentation.
Selected Scientific References
MSC identity, manufacturing and clinical translation
Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells.
Cytotherapy. 2006;8(4):315–317.
View publicationViswanathan S, et al. Mesenchymal stem versus stromal cells: ISCT position statement on MSC nomenclature.
Cytotherapy. 2019;21(10):1019–1024.
View publicationSensebé L, et al. Clinical-grade production of mesenchymal stem cells.
Bio-Medical Materials and Engineering. 2008;18(Suppl 1):S3–S10.
View publicationMoll G, et al. Improved MSC minimal criteria to maximise patient safety.
Trends in Molecular Medicine. 2022.
View publicationGalipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities.
Cell Stem Cell. 2018;22(6):824–833.
View publicationU.S. Food and Drug Administration. Consumer information concerning regenerative-medicine products, including stem-cell products.
Regulatory and patient-safety information.
View FDA information
Scientific and Clinical Information
Request information concerning CELLMEX cellular programmes
Physicians, researchers and institutions may request information concerning MSC biology, manufacturing, characterisation, clinical pathways and research collaboration.